U.S. News Rates Top GLP-1 Telehealth Companies for Weight Loss Support
As the popularity of GLP-1 medications for weight loss continues to rise, U.S. News & World Report has unveiled its inaugural ratings of telehealth companies providing these drugs. This initiative, announced on August 12, aims to assist consumers in navigating the expanding array of online options available for obtaining GLP-1 prescriptions. According to Gallup, approximately 11% of Americans are currently using GLP-1 medications, marking a significant increase. While many patients still obtain these prescriptions through traditional healthcare providers, a growing number—17%—are turning to telehealth services, as indicated by a recent KFF poll.
Gretel Schueller, managing editor of health at U.S. News & World Report, remarked on the current state of telehealth for GLP-1s, stating, "It is kind of the Wild West. Dozens of telehealth platforms are now selling GLP-1s. They are not all created equal. In some cases, there’s very little clinical oversight and support. Our ratings basically help guide people who are interested in buying them safely."
The convenience of telehealth platforms allows patients to bypass in-person visits, which can be particularly beneficial for those with time constraints or mobility issues. However, this shift has raised concerns regarding the adequacy of medical support provided through virtual consultations. Experts from Yale University have cautioned that some direct-to-consumer GLP-1 platforms may prioritize quick prescriptions over comprehensive patient care, potentially compromising safety.
A patient shared her experience with a telehealth provider, claiming that an incorrect dosage led to a GLP-1 overdose that required hospitalization. She noted that her only communication with the provider was via email, highlighting the potential pitfalls of impersonal care.
To determine the best telehealth platforms, U.S. News & World Report evaluated 20 companies that offer FDA-approved GLP-1 medications, such as Wegovy, Zepbound, and Foundayo. Companies that provide compounded versions of GLP-1s, which lack FDA oversight, were excluded from the ratings.
The evaluation process involved a combination of internal research and customer surveys, focusing on six key metrics: clinical support, screening rigor, transparency, insurance assistance, supplemental care, and customer satisfaction. Feedback from a survey of 1,251 U.S. adults who had used a GLP-1 through a telehealth platform in the past year was also considered.
The results yielded a list of 11 companies that received high ratings on a five-point scale, particularly excelling in patient safety aspects. Schueller noted that all rated companies earned top marks for their commitment to ensuring patient safety.
The ratings also recognized individual standout companies in various categories, assessing factors such as the availability of video consultations, the requirement for baseline blood work, and the provision of support for side effects, including anti-nausea medication. For instance, Found connects patients with board-certified clinicians specializing in obesity medicine, offering monthly video consultations and lab work.
Insurance coverage for GLP-1 medications can be complex, making platforms that assist with prior authorization and related paperwork particularly valuable. Additionally, the ratings considered the availability of nutritional support, progress tracking apps, and online community resources.
Schueller emphasized the importance of maintaining a balanced approach to weight loss with GLP-1 medications, stating, "We think of these as sort of miracle drugs, but the truth is, you’ve still got to do the work. Exercise is important to prevent muscle loss. Nutrient deficiencies are not uncommon with people in GLP-1s because you’re eating so little. So making sure you eat the right foods, get enough protein is really key."
The ratings also took into account patient experiences and their likelihood to recommend the companies. Positive feedback highlighted efficient communication with healthcare providers, transparency in costs, and quick medication delivery.
Experts advise patients considering telehealth options for GLP-1 prescriptions to prioritize platforms that facilitate easy access to medical professionals. Dr. Fatima Syed, an associate professor of medicine at Duke University, emphasized the importance of clear communication and real-time interactions with clinicians, ideally through video consultations rather than asynchronous chats.
Clinical oversight remains crucial, with recommendations for thorough medical history evaluations and blood work before prescribing GLP-1 medications. Schueller cautioned that these are prescription drugs that can have side effects and may pose risks for individuals with certain medical conditions or histories.
The challenges associated with weight loss using GLP-1 drugs include potential side effects such as nausea, nutritional deficiencies, and muscle loss. A joint advisory from several medical organizations stresses the need for a comprehensive care plan that includes nutritional and lifestyle counseling throughout the weight loss journey.




